Jump to the top of the page
Eason Hahm

Eason Hahm

Director, Biopharma

Boston skyline

About Eason

Eason Hahm is a director for William Blair based in the firm’s Boston office. She originally joined William Blair's investment banking team in 2012 and rejoined in 2018 after completing her M.B.A.

Notable Transactions

  • $40,266,204

    PIPE

    December 2022

  • $326,000,000

    has merged with

    November 2022

    William Blair is acting as financial advisor, capital markets advisor, and PIPE placement agent to Frazier Lifesciences Acquisition Corporation (NASDAQ: FLAC) in connection with its pending merger with NewAmsterdam Pharma Holding B.V.

    Read more
  • $234,600,000

    PIPE

    November 2022

    William Blair is acting as financial advisor, capital markets advisor, and PIPE placement agent to Frazier Lifesciences Acquisition Corporation (NASDAQ: FLAC) in connection with its pending merger with NewAmsterdam Pharma Holding B.V.

    Read more
  • $80,510,063

    Follow-on Offering

    September 2022

  • $258,750,018

    Follow-on Offering

    July 2022

  • $23,036,455

    Initial Public Offering

    December 2021

  • $168,000,000

    Initial Public Offering

    October 2021

  • $46,000,008

    Initial Public Offering

    October 2021

  • $306,681,983

    Initial Public Offering

    June 2021

  • $143,750,000

    Initial Public Offering

    March 2021

  • Rigorous pursuit of your success. Every transaction. Every time.

    Our investment bankers are 100 percent committed to your organization’s sustained success. By drawing on our deep industry and product experience as well as our dedicated global resources, we provide advisory and financing services that allow you to capitalize on today’s opportunities and anticipate tomorrow’s challenges.

    More about investment banking at William Blair
    Aerial view of highway interchange at night

    Biopharma

    The rapid and cost-effective development of innovative therapeutics and treatments is critical not just to public health, but to the functioning of society and economic activity. Leading drug developers, as well as their partners across the research, development, and manufacturing value chain, count on William Blair’s deep expertise in biopharma’s capital-raising and deal-making landscape.

    More about our biopharma expertise
    Petri dish

    About William Blair

    William Blair is a premier global boutique with expertise in investment banking, investment management, and private wealth management. We provide advisory services, strategies, and solutions to meet our clients’ evolving needs. As an independent and employee-owned firm, together with our strategic partners, we operate in more than 20 offices worldwide.*

    • 1935

      Year William Blair was founded

    • 1,900+

      Employees worldwide

    • 149 billion+

      Client assets

    • 89 Years

      Independent and employee-owned

    • 20+

      Offices worldwide

    • ~650

      Companies under coverage

    As of September 30, 2024
    *Includes strategic partnerships with Allier Capital, BDA Partners, and Poalim Capital Markets.

    More about William Blair affiliated entities

    This content is for informational and educational purposes only and not intended as investment advice or a recommendation to buy or sell any security. Investment advice and recommendations can be provided only after careful consideration of an investor's objectives, guidelines, and restrictions.

    Copyright © 2024 William Blair & Company, L.L.C. | Privacy Terms

    Are you sure you want to leave?

    Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

    For disclosure information, please visit www.williamblair.com/disclosures